The Effects of Corneal Collagen Cross-linking

Phase 3

Recruiting

• Conditions: Corneal Ectasia Disorders Including Keratoconus
• Interventions: Drug: CXL

• Registration Number: NCT01708538
• Lead Sponsor: Rush Eye Associates

Brief Summary

The corneal collagen cross-linking treatment has been used with increasing success to treat corneal dystrophies such as "keratoconus." Recent advances have allowed different techniques for performing this cross-linking treatment. This study investigates the effects of corneal cross-linking using different surgical techniques.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-10
• Study First Submitted: 2012-10-15
• Study First Submitted QC: 2012-10-16
• Study First Posted: 2012-10-17
• Status Verified: 2022-10
• Last Update Submitted: 2022-10-24
• Last Update Posted: 2022-10-26
• Primary Completion: 2024-10
• Study Completion: 2024-10

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Age 10-70, willing to participate, diagnosis of corneal ectasia disorder

Exclusion Criteria

• Unwilling or unable to participate in trial

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Epithelium off	CXL	Epi removed before CXL treatment
Epithelium on	CXL	Epi not removed during CXL treatment

Primary Outcome Measures

Name	Time	Method
Keratometry measurements	1 year	Average curvature of the cornea
Visual acuity	1 year	Best corrected Snellen acuity

Trial Locations

Locations (1)

Rush Eye Associates; 🇺🇸 Amarillo, Texas, United States